Skip to main content

Table 1 Summary of cohort characteristics in N = 1042 PSP cases, 171 CBD cases, and N = 910 controls

From: Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures

Variable

PSP cases (N = 1042)

CBD cases (N = 171)

Controls (N = 910)

Age (years)

75 (45, 98)

70 (46, 96)

79 (41, 102)

Sex

   

 Male

564 (54.1%)

89 (52.0%)

388 (42.6%)

 Female

478 (45.9%)

82 (48.0%)

522 (57.4%)

Age of onset (years)

68 (41, 90)

–

–

Disease duration (years)

7 (1, 32)

–

–

PSP clinical subtype

   

 Richardson

568 (74.4%)

–

–

 Non-Richardson

195 (25.6%)

–

–

Braak stage

   

 0

113 (14.8%)

20 (13.3%)

–

 I

127 (16.6%)

32 (21.3%)

–

 II

223 (29.2%)

50 (33.3%)

–

 III

234 (30.6%)

39 (26.0%)

–

 IV

50 (6.5%)

7 (4.7%)

–

 V

11 (1.4%)

1 (0.7%)

–

 VI

6 (0.8%)

1 (0.7%)

–

Thal phase

   

 0

336 (44.0%)

82 (54.7%)

–

 1

125 (16.4%)

30 (20.0%)

–

 2

52 (6.8%)

14 (9.3%)

–

 3

188 (24.6%)

19 (12.7%)

–

 4

43 (5.6%)

3 (2.0%)

–

 5

20 (2.6%)

2 (1.3%)

–

CB tau pathology score

1.50 (0.25, 2.36)

0.76 (0.23, 1.75)

–

NFT tau pathology score

2.23 (0.83, 2.89)

2.19 (0.99, 2.67)

–

TA/AP tau pathology score

1.00 (0.06, 2.00)

0.52 (0.24, 1.04)

–

NT tau pathology score

2.15 (0.35, 2.90)

2.52 (1.23, 2.95)

–

  1. The sample median (minimum, maximum) is given for continuous variables. CB = coiled bodies; NFT = neurofibrillary tangles; TA = tufted astrocytes; AP = astrocytic plaques; NT = neuropil threads